口腔外科領域におけるCefoperazone(T-1551)の基礎的臨床的研究 (Cefoperazone<特集>)
スポンサーリンク
概要
- 論文の詳細を見る
Cefoperazone (CPZ, T-1551), a new cephalosporin derivative synthesized in Japan, has been evaluated experimentally and clinically in the oral surgical field. Results are summarized as follows.<BR>1) The minimal inhibitory concentrations (MICs) of CPZ against gram-positive cocci (20 strains) isolated from the patients with oral infections showed similar to those of cefazolin, while MICs against gram-negative rods (54 strains) were distributed in the range of 25 jig/ml or less.<BR>2) The concentrations of serum and oral tissues were investigated with 10 rabbits and the following results were obtained. The mean serum concentration of CPZ at 60 min. after intravenous injection of 40 mg/kg showed 107.7±38.8 jig/ml, and 27.5±7.7μg/ml at 120 min. after the injection. The level of mandibular bone marrow showed 10.6±5.7 μg/g at 60 min. after and 6.3±2.5 jig/ml at 120 min. after intravenous injection.<BR>According to these experimental results, CPZ was applied clinically to 26 cases in order to determine the concentrations of CPZ in the serum and oral tissues. The concentration of CPZ in mandibular bone marrow reached 25% of serum level. The mean serum level was 115.35 ±50.02 jig/ml at the final point of the drip infusion for 1 hr.(20 mg/kg) and 6.5 ±4.06 μg/ml at 7 hr. after the injection.<BR>3) CPZ was administered by the drip infusion into 23 patients with the various infections in the oral surgical field. The therapeutic effects were excellent in 13 cases (56.5%), effective in 4 cases (17.4%), ineffective in 6 cases (26.1%) and the efficacy rate was 73.9%.<BR>4) No serious side effect was observed except one case of slight diarrhoea.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.